The risk of second primary malignancies in colorectal cancer patients using calcium channel blockers.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
received:
18
10
2022
accepted:
06
02
2023
entrez:
1
3
2023
pubmed:
2
3
2023
medline:
4
3
2023
Statut:
epublish
Résumé
Calcium channel blockers are among the most commonly used agents in the treatment of cardiovascular diseases. There are several known side-effects associated with their long-term use, whereas other potential adverse effects are yet to be proven. This study aims to evaluate the association between calcium channel blockers exposure and the incidence of second primary malignancy. We established a cohort of 1401 patients with colorectal cancer diagnosed in our institution between January 2003 and December 2016. Patients were followed-up until December 2020. The tumor characteristics and basic clinical data including medication information were obtained from the hospital information system database. Second malignancy was detected in 301 patients (21.5%), and occurred in 27.8% of patients who used calcium channel blockers compared to only 19.9% among non-users. Their use was associated with an increased incidence of bladder cancer in particular. Subanalysis of patients with second malignancy displayed a higher proportion of right-sided colon cancer compared to rectal carcinoma in non-users. Survival analysis revealed significantly better outcomes in early-stage colorectal cancer patients without a history of calcium channel blockers treatment or second primary malignancy.
Identifiants
pubmed: 36859505
doi: 10.1038/s41598-023-29535-7
pii: 10.1038/s41598-023-29535-7
pmc: PMC9977965
doi:
Substances chimiques
Calcium Channel Blockers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3490Informations de copyright
© 2023. The Author(s).
Références
BMJ Open. 2016 Jan 08;6(1):e009147
pubmed: 26747033
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2512-22
pubmed: 26072287
Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2502-11
pubmed: 25150047
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt B):1786-1794
pubmed: 29842892
Clin Ther. 2020 Sep;42(9):1715-1727.e2
pubmed: 32807506
Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):711-8
pubmed: 24829113
Eur J Cancer Prev. 2019 Mar;28(2):76-80
pubmed: 29280915
J Clin Med. 2021 Feb 15;10(4):
pubmed: 33671916
Aging (Albany NY). 2020 Jan 22;12(2):1545-1562
pubmed: 31968309
Hypertension. 1997 May;29(5):1091-4
pubmed: 9149671
Cancer. 1997 Oct 15;80(8):1438-47
pubmed: 9338468
Epidemiology. 2016 Jul;27(4):594-601
pubmed: 27031042
JAMA Intern Med. 2014 Oct;174(10):1700-1
pubmed: 25133435
Lancet. 1996 Aug 24;348(9026):493-7
pubmed: 8757150
Nat Rev Cancer. 2007 Jul;7(7):519-30
pubmed: 17585332
FASEB J. 1995 Feb;9(2):219-28
pubmed: 7781924
Drug Saf. 2018 Jun;41(6):555-564
pubmed: 29484611
Front Pharmacol. 2021 May 13;12:609901
pubmed: 34054514
Nat Rev Cancer. 2008 May;8(5):361-75
pubmed: 18432251
Cold Spring Harb Perspect Biol. 2019 Aug 1;11(8):
pubmed: 31088826
Cancer Med. 2021 Aug;10(15):5347-5357
pubmed: 34184420
Lancet. 1997 Feb 22;349(9051):525-8
pubmed: 9048789
JAMA Intern Med. 2013 Sep 23;173(17):1629-37
pubmed: 23921840
J Hypertens. 1998 Jan;16(1):119-24
pubmed: 9533425
Aging (Albany NY). 2018 May 24;10(5):1166-1181
pubmed: 29846174
Breast Cancer Res Treat. 2015 Feb;150(1):219-29
pubmed: 25701121
Lancet Oncol. 2021 Apr;22(4):558-570
pubmed: 33794209
Am J Epidemiol. 2017 Feb 15;185(4):264-273
pubmed: 28186527
JAMA. 1998 Apr 1;279(13):1000-4
pubmed: 9533498
Prostate. 2013 Jun;73(8):865-72
pubmed: 23280547
Methods Mol Biol. 2009;471:85-105
pubmed: 19109776
ESMO Open. 2017 May 2;2(2):e000172
pubmed: 28761745
Circ J. 2010 Mar;74(3):567-71
pubmed: 20118567
Proc Soc Exp Biol Med. 1983 Oct;174(1):16-9
pubmed: 6634703
J Am Coll Cardiol. 1999 Dec;34(7):1857-66
pubmed: 10588195
Cancer Sci. 2021 May;112(5):1997-2005
pubmed: 33660381